# Astronics Corp: financial statements, quarterly

ATRO · Nasdaq · CIK 8063 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atro.md) · [Financials](/companies/atro/financials.md) · [Filings](/companies/atro/filings.md) · [Insiders](/companies/atro/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atro/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [163](/filings/0000008063-24-000059.md) | [195](/filings/0000008063-25-000017.md) | [185](/filings/0000008063-25-000035.md) | [198](/filings/0000008063-25-000059.md) | [204](/filings/0000008063-25-000086.md) | [209](/filings/0000008063-26-000021.md) | [206](/filings/0000008063-26-000025.md) | [205](/filings/0000008063-26-000043.md) | [211](/filings/0000008063-25-000086.md) | [240](/filings/0000008063-26-000021.md) | [231](/filings/0000008063-26-000025.md) | [260](/filings/0000008063-26-000043.md) |
| Cost of revenue | $m | [142](/filings/0000008063-24-000059.md) | [102 d](/filings/0000008063-26-000021.md) | [138](/filings/0000008063-25-000035.md) | [143](/filings/0000008063-25-000059.md) | [148](/filings/0000008063-25-000086.md) | [146 d](/filings/0000008063-26-000021.md) | [145](/filings/0000008063-26-000025.md) | [152](/filings/0000008063-26-000043.md) | [147](/filings/0000008063-25-000086.md) | [160 d](/filings/0000008063-26-000021.md) | [155](/filings/0000008063-26-000025.md) | [173](/filings/0000008063-26-000043.md) |
| Gross profit | $m | [20.6](/filings/0000008063-24-000059.md) | [40.0](/filings/0000008063-25-000017.md) | [47.5](/filings/0000008063-25-000035.md) | [55.6](/filings/0000008063-25-000059.md) | [55.2](/filings/0000008063-25-000086.md) | [62.1](/filings/0000008063-26-000021.md) | [60.8](/filings/0000008063-26-000025.md) | [52.8](/filings/0000008063-26-000043.md) | [64.5](/filings/0000008063-25-000086.md) | [80.0](/filings/0000008063-26-000021.md) | [75.1](/filings/0000008063-26-000025.md) | [86.9](/filings/0000008063-26-000043.md) |
| Research and development | $m | [14.1](/filings/0000008063-24-000059.md) | [14.2 d](/filings/0000008063-26-000021.md) | [13.3](/filings/0000008063-25-000035.md) | [14.2](/filings/0000008063-25-000059.md) | [12.5](/filings/0000008063-25-000086.md) | [12.1 d](/filings/0000008063-26-000021.md) | [11.1](/filings/0000008063-26-000025.md) | [11.6](/filings/0000008063-26-000043.md) | [10.2](/filings/0000008063-25-000086.md) | [10.6 d](/filings/0000008063-26-000021.md) | [12.1](/filings/0000008063-26-000025.md) | [10.9](/filings/0000008063-26-000043.md) |
| Selling, general and administrative | $m | [35.1](/filings/0000008063-24-000059.md) | [32.2 d](/filings/0000008063-26-000021.md) | [32.5](/filings/0000008063-25-000035.md) | [33.8](/filings/0000008063-25-000059.md) | [34.4](/filings/0000008063-25-000086.md) | [41.2 d](/filings/0000008063-26-000021.md) | [36.6](/filings/0000008063-26-000025.md) | [36.5](/filings/0000008063-26-000043.md) | [31.2](/filings/0000008063-25-000086.md) | [33.9 d](/filings/0000008063-26-000021.md) | [35.8](/filings/0000008063-26-000025.md) | [35.6](/filings/0000008063-26-000043.md) |
| Operating income | $m | [(14.5)](/filings/0000008063-24-000059.md) | [7.8 d](/filings/0000008063-26-000021.md) | [1.7](/filings/0000008063-25-000035.md) | [7.6](/filings/0000008063-25-000059.md) | [8.4](/filings/0000008063-25-000086.md) | [8.9 d](/filings/0000008063-26-000021.md) | [13.1](/filings/0000008063-26-000025.md) | [4.8](/filings/0000008063-26-000043.md) | [23.1](/filings/0000008063-25-000086.md) | [35.5 d](/filings/0000008063-26-000021.md) | [27.2](/filings/0000008063-26-000025.md) | [40.5](/filings/0000008063-26-000043.md) |
| Interest expense | $m | [(6.0)](/filings/0000008063-24-000059.md) | not reported | not reported | [(5.9)](/filings/0000008063-24-000048.md) | [(6.2)](/filings/0000008063-24-000059.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(3.8)](/filings/0000008063-24-000059.md) | [(5.4) d](/filings/0000008063-26-000021.md) | [(1.4)](/filings/0000008063-25-000035.md) | [(0.3)](/filings/0000008063-25-000059.md) | [6.6](/filings/0000008063-25-000086.md) | [3.4 d](/filings/0000008063-26-000021.md) | [0.6](/filings/0000008063-26-000025.md) | [0.5](/filings/0000008063-26-000043.md) | [(1.2)](/filings/0000008063-25-000086.md) | [2.6 d](/filings/0000008063-26-000021.md) | [(0.8)](/filings/0000008063-26-000025.md) | [2.8](/filings/0000008063-26-000043.md) |
| Net income | $m | [(17.0)](/filings/0000008063-24-000059.md) | [7.0](/filings/0000008063-25-000017.md) | [(3.2)](/filings/0000008063-25-000035.md) | [1.5](/filings/0000008063-25-000059.md) | [(11.7)](/filings/0000008063-25-000086.md) | [(2.8)](/filings/0000008063-26-000021.md) | [9.5](/filings/0000008063-26-000025.md) | [1.3](/filings/0000008063-26-000043.md) | [(11.1)](/filings/0000008063-25-000086.md) | [29.6](/filings/0000008063-26-000021.md) | [25.5](/filings/0000008063-26-000025.md) | [35.1](/filings/0000008063-26-000043.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0000008063-24-000059.md) | [0.20](/filings/0000008063-25-000017.md) | [(0.09)](/filings/0000008063-25-000035.md) | [0.04](/filings/0000008063-25-000059.md) | [(0.34)](/filings/0000008063-25-000086.md) | [(0.08)](/filings/0000008063-26-000021.md) | [0.26](/filings/0000008063-26-000025.md) | [0.03](/filings/0000008063-26-000043.md) | [(0.31)](/filings/0000008063-25-000086.md) | [0.78](/filings/0000008063-26-000021.md) | [0.67](/filings/0000008063-26-000025.md) | [0.75](/filings/0000008063-26-000043.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0000008063-24-000059.md) | [0.20](/filings/0000008063-25-000017.md) | [(0.09)](/filings/0000008063-25-000035.md) | [0.04](/filings/0000008063-25-000059.md) | [(0.34)](/filings/0000008063-25-000086.md) | [(0.08)](/filings/0000008063-26-000021.md) | [0.27](/filings/0000008063-26-000025.md) | [0.03](/filings/0000008063-26-000043.md) | [(0.31)](/filings/0000008063-25-000086.md) | [0.83](/filings/0000008063-26-000021.md) | [0.71](/filings/0000008063-26-000025.md) | [0.82](/filings/0000008063-26-000043.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.0](/filings/0000008063-24-000059.md) | [4.8](/filings/0000008063-25-000017.md) | [5.3](/filings/0000008063-25-000035.md) | [2.9](/filings/0000008063-25-000059.md) | [5.2](/filings/0000008063-25-000086.md) | [9.3](/filings/0000008063-26-000021.md) | [24.8](/filings/0000008063-26-000025.md) | [13.5](/filings/0000008063-25-000059.md) | [13.5](/filings/0000008063-25-000086.md) | [18.2](/filings/0000008063-26-000043.md) | [11.9](/filings/0000008063-26-000025.md) | [9.0](/filings/0000008063-26-000043.md) |
| Current assets | $m | [381](/filings/0000008063-23-000059.md) | [390](/filings/0000008063-25-000017.md) | [392](/filings/0000008063-24-000029.md) | [412](/filings/0000008063-24-000048.md) | [424](/filings/0000008063-24-000059.md) | [426](/filings/0000008063-26-000021.md) | [432](/filings/0000008063-25-000035.md) | [419](/filings/0000008063-25-000059.md) | [433](/filings/0000008063-25-000086.md) | [438](/filings/0000008063-26-000043.md) | [469](/filings/0000008063-26-000025.md) | [486](/filings/0000008063-26-000043.md) |
| Total assets | $m | [631](/filings/0000008063-23-000059.md) | [634](/filings/0000008063-25-000017.md) | [630](/filings/0000008063-24-000029.md) | [645](/filings/0000008063-24-000048.md) | [652](/filings/0000008063-24-000059.md) | [649](/filings/0000008063-26-000021.md) | [662](/filings/0000008063-25-000035.md) | [647](/filings/0000008063-25-000059.md) | [682](/filings/0000008063-25-000086.md) | [707](/filings/0000008063-26-000043.md) | [747](/filings/0000008063-26-000025.md) | [761](/filings/0000008063-26-000043.md) |
| Current liabilities | $m | [158](/filings/0000008063-23-000059.md) | [143](/filings/0000008063-25-000017.md) | [151](/filings/0000008063-24-000029.md) | [141](/filings/0000008063-24-000048.md) | [150](/filings/0000008063-24-000059.md) | [156](/filings/0000008063-26-000021.md) | [158](/filings/0000008063-25-000035.md) | [138](/filings/0000008063-25-000059.md) | [151](/filings/0000008063-25-000086.md) | [141](/filings/0000008063-26-000043.md) | [158](/filings/0000008063-26-000025.md) | [163](/filings/0000008063-26-000043.md) |
| Total liabilities | $m | [398](/filings/0000008063-23-000059.md) | [384](/filings/0000008063-25-000017.md) | [378](/filings/0000008063-24-000029.md) | [387](/filings/0000008063-24-000048.md) | [402](/filings/0000008063-24-000059.md) | [393](/filings/0000008063-26-000021.md) | [395](/filings/0000008063-25-000035.md) | [375](/filings/0000008063-25-000059.md) | [573](/filings/0000008063-25-000086.md) | [567](/filings/0000008063-26-000043.md) | [585](/filings/0000008063-26-000025.md) | [563](/filings/0000008063-26-000043.md) |
| Long-term debt | $m | [160](/filings/0000008063-23-000059.md) | [159](/filings/0000008063-25-000017.md) | [153](/filings/0000008063-24-000029.md) | [173](/filings/0000008063-24-000048.md) | [178](/filings/0000008063-24-000059.md) | [169](/filings/0000008063-26-000021.md) | [160](/filings/0000008063-25-000035.md) | [159](/filings/0000008063-25-000059.md) | [334](/filings/0000008063-25-000086.md) | [334](/filings/0000008063-26-000043.md) | [335](/filings/0000008063-26-000025.md) | [310](/filings/0000008063-26-000043.md) |
| Current portion of debt | $m | [9.0](/filings/0000008063-23-000059.md) | [9.0](/filings/0000008063-25-000017.md) | [9.0](/filings/0000008063-24-000029.md) | [1.3](/filings/0000008063-24-000048.md) | [0.6](/filings/0000008063-24-000059.md) | [0.0](/filings/0000008063-25-000017.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [232](/filings/0000008063-24-000059.md) | [250](/filings/0000008063-26-000021.md) | [252](/filings/0000008063-25-000035.md) | [258](/filings/0000008063-25-000059.md) | [249](/filings/0000008063-25-000086.md) | [256](/filings/0000008063-26-000021.md) | [267](/filings/0000008063-26-000025.md) | [272](/filings/0000008063-26-000043.md) | [109](/filings/0000008063-25-000086.md) | [140](/filings/0000008063-26-000043.md) | [162](/filings/0000008063-26-000025.md) | [198](/filings/0000008063-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.1) d](/filings/0000008063-24-000059.md) | [(1.7) d](/filings/0000008063-26-000021.md) | [2.0](/filings/0000008063-25-000035.md) | [(6.3) d](/filings/0000008063-25-000059.md) | [8.4 d](/filings/0000008063-25-000086.md) | [26.4 d](/filings/0000008063-26-000021.md) | [20.6](/filings/0000008063-26-000025.md) | [(7.6) d](/filings/0000008063-26-000043.md) | [34.2 d](/filings/0000008063-25-000086.md) | [27.6 d](/filings/0000008063-26-000021.md) | [10.6](/filings/0000008063-26-000025.md) | [30.1 d](/filings/0000008063-26-000043.md) |
| Capital expenditure | $m | [2.2 d](/filings/0000008063-24-000059.md) | [1.6 d](/filings/0000008063-26-000021.md) | [1.6](/filings/0000008063-25-000035.md) | [1.8 d](/filings/0000008063-25-000059.md) | [1.9 d](/filings/0000008063-25-000086.md) | [3.2 d](/filings/0000008063-26-000021.md) | [2.1](/filings/0000008063-26-000025.md) | [4.6 d](/filings/0000008063-26-000043.md) | [13.2 d](/filings/0000008063-25-000086.md) | [11.8 d](/filings/0000008063-26-000021.md) | [11.2](/filings/0000008063-26-000025.md) | [5.7 d](/filings/0000008063-26-000043.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.2](/filings/0000008063-23-000059.md) | [32.5](/filings/0000008063-24-000029.md) | [32.6](/filings/0000008063-24-000048.md) | [33.0](/filings/0000008063-24-000059.md) | [34.9](/filings/0000008063-25-000035.md) | [35.5](/filings/0000008063-25-000059.md) | [35.0](/filings/0000008063-25-000086.md) | [43.0](/filings/0000008063-26-000025.md) | [43.6](/filings/0000008063-26-000043.md) | [35.4](/filings/0000008063-25-000086.md) | [38.2](/filings/0000008063-26-000025.md) | [46.5](/filings/0000008063-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,282,681 at 2023-03-06, from the cover of the [10-K filed 2023-03-10](/filings/0000008063-23-000015.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.